CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of Ltd, has entered into a marketing and distribution agreement with , a leading European healthcare and pharmaceuticals company. Under the terms of the agreement, STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories, including France and Germany. This strategic partnership is expected to expand CuraTeQ’s market reach and drive revenue growth by leveraging STADA’s established distribution network in EU markets. New brand names will be created and registered for each biosimilar, enhancing their market presence. The agreement signifies a significant step for CuraTeQ in strengthening its position in the European biosimilars market, although it is not classified as a material event under Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Add us as preferred source on Google
TOPICS: Aurobindo Pharma CuraTeQ Biologics STADA Arzneimittel AG